StocksMediumUpdated•Originally published 2 November 2026•Updated 3 November 2026•
1 min read
CRISPR Therapeutics Q3 Loss Wider Than Expected Despite Casgevy Sales Growth
Key Facts
1Casgevy sales reached approximately $99 million in Q3, representing a 30% increase from the second quarter.
2The company reported a net loss of $111.4 million, compared to a loss of $106.4 million a year earlier.
CRISPR Therapeutics reported a quarterly loss of $1.15 per share, wider than the Zacks Consensus Estimate of a $1.06 loss per share. According to reports from The Motley Fool, the company's total net loss reached $111.4 million for the third quarter of 2026, compared to a loss of $106.4 million in the prior year.
Sales of the therapy Casgevy reached approximately $99 million during the period, marking a 30% increase over the second quarter. CRSP closed at $51.42 on October 30, 2026, with the stock trading between a low of $50.6 and a high of $54.1 on that date prior to the release of the financial results.